Vantage logo

Reality bites for Macrogenics 

Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study. 

Vantage logo

Hard knocks for brain cancer, again

In the wake of two phase III glioblastoma failures this month, from Abbvie and Bristol-Myers Squibb, hopes dim for another big readout from Tocagen.